The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Main results from the ANDROMEDA study
Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, discusses the main findings from the ANDROMEDA study (NCT03201965), comparing efficacy and safety of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).
